viernes, 26 de junio de 2015

Ondansetron y embarazo/Ondansetron and pregnancy

Actualización en riesgo materno. ¿Es el ondansetron seguro durante el embarazo?
Motherisk update. Is ondansetron safe for use during pregnancy?
Koren G.
Can Fam Physician. 2012 Oct;58(10):1092-3.
Abstract
QUESTION: While I usually prescribe doxylamine-pyridoxine for morning sickness, some of my patients with severe nausea and vomiting of pregnancy (NVP) receive ondansetron in hospital. I have read some new precautions recommended by the US Food and Drug Administration (FDA). Is ondansetron safe to use during pregnancy?
ANSWER: During the past decade ondansetron has been increasingly used in the United States for NVP, owing to the lack of an FDA-approved drug for this condition. While fetal safety data for doxylamine-pyridoxine are based on more than a quarter of a million pregnancies, the fetal safety data for ondansetron are based on fewer than 200 births. Moreover, a recent case-control study suggested there was an increased risk of cleft palate associated with ondansetron. Recently, the FDA issued a warning about potentially serious QT prolongation and torsade de pointes associated withondansetron use; the warning included a list of precautions and tests that must be followed. The drug is not labeled for use in NVP in either the United States or Canada. Based on the data available today, ondansetron use cannot be assumed to be safe during pregnancy.
PDF 
Uso "fuera de etiqueta" de ondansetron en el embarazo, en Australia Occidental
Off-label use of ondansetron in pregnancy in Western Australia.
Colvin L, Gill AW, Slack-Smith L, Stanley FJ, Bower C.
Biomed Res Int. 2013;2013:909860. doi: 10.1155/2013/909860. Epub 2013 Dec 12.
Abstract
AIMS: Nausea and vomiting of pregnancy is the most common medical condition in pregnancy. There is an increasing trend to prescribeondansetron although its safety for use in pregnancy has not been established. METHODS: Exposed pregnancies were all births in Western Australia, 2002-2005, where the mother was dispensed ondansetron under the Australian Pharmaceutical Benefits Scheme, compared with all other births during the same period. Outcomes investigated include maternal and child characteristics, birth defects, pregnancy, and delivery characteristics.
RESULTS: There were 96,968 births from 2002 to 2005. Ondansetron was dispensed to 251 pregnant women during this period. The women dispensed ondansetron were more likely to be privately insured (OR: 5.8; 95% CI: 4.3-7.9), to be Caucasian (3.3; 1.9-5.7), not to smoke during their pregnancy (2.9; 1.8-4.7), to have a multiple birth (2.7; 1.5-5.0), and to have used fertility treatment (1.8; 1.0-3.4). There was a small but not significantly increased risk of a major birth defect with first trimester exposure (1.2; 0.6-2.2). CONCLUSIONS:Our study did not detect any adverse outcomes from the use of ondansetron in pregnancy but could not conclude that ondansetronis safe to use in pregnancy.
PDF
Ondansetron en el embarazo y riesgo de resultados adversos
Ondansetron in pregnancy and risk of adverse fetal outcomes.
Pasternak B, Svanström H, Hviid A.
N Engl J Med. 2013 Feb 28;368(9):814-23. doi: 10.1056/NEJMoa1211035.
Abstract
BACKGROUND: Ondansetron is frequently used to treat nausea and vomiting during pregnancy, but the safety of this drug for the fetus has not been well studied. METHODS:
We investigated the risk of adverse fetal outcomes associated with ondansetron administered during pregnancy. From a historical cohort of 608,385 pregnancies in Denmark, women who were exposed to ondansetron and those who were not exposed were included, in a 1:4 ratio, in propensity-score-matched analyses of spontaneous abortion (1849 exposed women vs. 7396 unexposed women), stillbirth (1915 vs. 7660), any major birth defect (1233 vs. 4932), preterm delivery (1792 vs. 7168), and birth of infants at low birth weight and small for gestational age (1784 vs. 7136). In addition, estimates were adjusted for hospitalization for nausea and vomiting during pregnancy (as a proxy for severity) and the use of other antiemetics. RESULTS: Receipt of ondansetron was not associated with a significantly increased risk of spontaneous abortion, which occurred in 1.1% of exposed women and 3.7% of unexposed women during gestational weeks 7 to 12 (hazard ratio, 0.49; 95% confidence interval [CI], 0.27 to 0.91) and in 1.0% and 2.1%, respectively, during weeks 13 to 22 (hazard ratio, 0.60; 95% CI, 0.29 to 1.21). Ondansetron also conferred no significantly increased risk of stillbirth (0.3% for exposed women and 0.4% for unexposed women; hazard ratio, 0.42; 95% CI, 0.10 to 1.73), any major birthdefect (2.9% and 2.9%, respectively; prevalence odds ratio, 1.12; 95% CI, 0.69 to 1.82), preterm delivery (6.2% and 5.2%; prevalence odds ratio, 0.90; 95% CI, 0.66 to 1.25), delivery of a low-birth-weight infant (4.1% and 3.7%; prevalence odds ratio, 0.76; 95% CI, 0.51 to 1.13), or delivery of a small-for-gestational-age infant (10.4% and 9.2%; prevalence odds ratio, 1.13; 95% CI, 0.89 to 1.44). CONCLUSIONS: Ondansetron taken during pregnancy was not associated with a significantly increased risk of adverse fetal outcomes. (Funded by the Danish Medical Research Council.).
PDF
Medicamentos para nausea y vomito en el embarazo y el riesgo de defectos de nacimiento seleccionados.
Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects.
Anderka M1, Mitchell AA, Louik C, Werler MM, Hernández-Diaz S, Rasmussen SA; National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol. 2012 Jan;94(1):22-30. doi: 10.1002/bdra.22865. Epub 2011 Nov 19.
Abstract
BACKGROUND: Nausea and vomiting of pregnancy (NVP) occurs in up to 80% of pregnant women, but its association with birth outcomes is not clear. Several medications are used for the treatment of NVP; however, data are limited on their possible associations with birth defects. METHODS: Using data from the National Birth Defects Prevention Study (NBDPS)-a multi-site, population-based, case-control study-we examined whether NVP or its treatment was associated with the most common noncardiac defects in the NBDPS (nonsyndromic cleft lip with or without cleft palate [CL/P], cleft palate alone [CP], neural tube defects, and hypospadias) compared with randomly selected nonmalformed live births. RESULTS: Among the 4524 cases and 5859 controls included in this study, 67.1% reported first-trimester NVP, and 15.4% of them reported using at least one agent for NVP. Nausea and vomiting of pregnancy was not associated with CP or neural tube defects, but modest risk reductions were observed for CL/P (adjusted odds ratio [aOR] = 0.87; 95% confidence interval [CI], 0.77-0.98) and hypospadias (aOR = 0.84; 95% CI, 0.72-0.98). Regarding treatments for NVP in the first trimester, the following adjusted associations were observed with an increased risk: proton pump inhibitors and hypospadias (aOR = 4.36; 95% CI, 1.21-15.81), steroids and hypospadias (aOR = 2.87; 95% CI, 1.03-7.97), and ondansetron and CP (aOR = 2.37; 95% CI, 1.18-4.76), whereas antacids were associated with a reduced risk for CL/P (aOR = 0.58; 95% CI, 0.38-0.89). CONCLUSIONS: NVP was not observed to be associated with an increased risk of birth defects; however, possible risks related to three treatments (i.e., proton pump inhibitors, steroids and ondansetron), which could be chance findings, warrant further investigation.
PDF
Tratamiento de las náuseas del embarazo en los Estados Unidos. Se necesitan cambios en la prescripción
Treating morning sickness in the United States--changes in prescribing are needed.
Koren G.
Am J Obstet Gynecol. 2014 Dec;211(6):602-6. doi: 10.1016/j.ajog.2014.08.017. Epub 2014 Aug 20.
Abstract
Presently, 97.7% of prescriptions for the treatment of nausea and vomiting in pregnancy in the United States are with medications not labeled for use in pregnancy, not indicated for nausea and vomiting in pregnancy, and not classified as safe in pregnancy by the Food and Drug Administration. The use of ondansetron for nausea and vomiting in pregnancy has increased from 50,000 monthly prescriptions in 2008 to 110,000 at the end of 2013, despite unresolved issues regarding fetal safety and Food and Drug Administration warnings about serious dysrhythmias. In April 2013, the Food and Drug Administration approved the combination of doxylamine and pyridoxine, specifically for nausea and vomiting in pregnancy symptoms. Now that a safe and effective drug is available in the United States, there is no reason for women to be exposed to a drug of unproven maternal and fetalsafety.
PDF
Nausea y vomito en el embarazo temprano
Nausea and vomiting in early pregnancy.
Festin M.
BMJ Clin Evid. 2009 Jun 3;2009. pii: 1405.
Abstract
INTRODUCTION: More than half of pregnant women suffer from nausea and vomiting, which typically begins by the 4th week and disappears by the 16th week of pregnancy. The cause of nausea and vomiting in pregnancy is unknown, but may be due to the rise in human chorionic gonadotrophin concentration. In 1 in 200 women, the condition progresses to hyperemesis gravidarum, which is characterised by prolonged and severe nausea and vomiting, dehydration, and weight loss. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatment for nausea and vomiting in early pregnancy? What are the effects of treatments for hyperemesis gravidarum? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2008 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 30 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: acupressure; acupuncture; antihistamines; corticosteroids; corticotrophins; diazepam; dietary interventions other than ginger; domperidone; ginger; metoclopramide; ondansetron; phenothiazines; and pyridoxine (vitamin B6).
PDF
Atentamente
Anestesia y Medicina del Dolor

jueves, 25 de junio de 2015

Ondansetron

Estudio comparativo de ondansetron y dosis subhipnóticas de propofol en el control y tratamiento del prurito inducido por sufentanil intratecal en cesárea electiva
The comparative study of intravenous Ondansetron and sub-hypnotic Propofol dose in control and treatment of intrathecal Sufentanil-induced pruritus in elective caesarean surgery.
Hirmanpour A, Safavi M, Honarmand A, Hosseini AZ, Sepehrian M.
J Res Pharm Pract. 2015 Apr-Jun;4(2):57-63. doi: 10.4103/2279-042X.155751.
Abstract
OBJECTIVE: Pruritus is a common and disturbing side effect of neuraxial opioids after cesarean section. The purpose of this study was to compare the efficacy of intravenous ondansetron and sub-hypnotic dose of propofol in control and treatment of intrathecal sufentanil induced pruritus in cesarean surgery. METHODS: Totally, 90 parturient with American Society of Anesthesiology physical status grade I-II, undergoing spinal anesthesia with 2.5 μg sufentanil and 10 mg bupivacaine 0.5% were enrolled to this randomized, prospective, double-blind study. The women were randomly assigned to two groups who received 8 mg ondansetron or 10 mg propofol to treat pruritus grade ≥3. The patient was evaluated after 5 min and in the lack of successful treatment, the doses of two drugs repeated and if the pruritus is on-going, the exact treatment with naloxone was done. FINDINGS: The incidence of pruritus was 69.3%. Both groups were well-matched. The peak time pruritus was 30-75 min after injection. The percentage of individuals consumed naloxone were 6.8% and 15.9% in ondansetron and propofol groups, respectively (P = 0.18). The mean score of satisfaction (according to visual analog scale criteria) was 9.09 ± 1.1 in ondansetron group and 9.3 ± 1.07 in the propofol group (P = 0.39). CONCLUSION: Ondansetrone and sub-hypnotic dose of propofol are both safe and well-tolerated. Due to their same efficacy in the treatment of intrathecal sufentanil-induced pruritus, they can be widely used in clinical practice. KEYWORDS: Caesarean surgery; Ondansetron; Propofol; intrathecal opioid; pruritus
PDF
 
Administración profiláctica de ondansetron en la prevención de prurito y nausea y vomito inducidos por morfina intratecal en pacientes con cesárea.
Prophylactic administration of ondansetron in prevention of intrathecal morphine-induced pruritus and post-operative nausea and vomiting in patients undergoing caesarean section.
Koju RB, Gurung BS, Dongol Y.
BMC Anesthesiol. 2015 Feb 17;15:18. doi: 10.1186/1471-2253-15-18.
Abstract
BACKGROUND: Intrathecal morphine is commonly used for post caesarean analgesia. However, their use is frequently associated with the incidence of troublesome side effects such as nausea, vomiting and pruritus. Various mechanisms have been postulated for the opioid-inducedpruritus, with a variety of medications with different mechanisms of actions formulated for the prevention and treatment. But, the results are inconsistent and hence the prevention and treatment of opioid-induced pruritus still remains a challenge. Ondansetron which is antiemetic, non-sedative and has no antianalgesic effect is an antagonist to 5-HT3 receptor, the receptor with which opioids interacts and imparts its effects.Ondansetron, thus, would be an attractive treatment strategy for both opioid-induced pruritus and post-operative nausea and vomiting. METHODS: After the approval from institutional review committee and written consent received from the patient, 50 healthy parturients of ASA I and II physical status undergoing caesarean section under spinal anaesthesia were enrolled for the study. They were randomly categorized into placebo group (2 ml normal saline) and treatment group (2 ml of 4 mg ondansetron), each group containing 25 patients. Pruritus and post-operative nausea and vomiting scores were recorded up to 24 hours after the administration of intrathecal morphine. Statistical analysis was performed using chi-square test. RESULTS: The incidence, severity and necessity of treatment for pruritus in the treatment group was significantly reduced compared to the placebo group (16% vs 88%). Similarly, the risk of post-operative nausea and vomiting in the treatment group was less compared to the placebo group (8% vs 56%). CONCLUSION: Prophylactic administration of ondansetron to parturients receiving intrathecal morphine for post-operative analgesia provides a significant reduction of intrathecal morphine-induced pruritus and nausea and vomiting.
PDF
Atentamente
Anestesia y Medicina del Dolor

miércoles, 24 de junio de 2015

Recordarán a Rafael Bernal con curso sobre novela criminal y ciclo de cine en el CC Elena Garro


Fuente
Este artículo es originalmente publicado en:

http://www.orgullosocitadino.com/2015/06/recordaran-rafael-bernal-con-curso.html

Un Orgulloso Citadino


Posted: 22 Jun 2015 04:59 PM PDT
Recordarán a Rafael Bernal con curso sobre novela criminal y ciclo de cine en el CC Elena Garro

El Centro Cultural Elena Garro brinda un homenaje al escritor Rafael Bernal, a cien años de su nacimiento, con la programación de dos actividades que tienen como marco el llamado género negro, cultivado con éxito en varias de las obras de Bernal. El pretexto perfecto será la más memorable de las novelas policiacas hechas en este país: El complot mongol, libro de culto entre los amantes de este género, y obra con la que Bernal alcanzara la inmortalidad en las letras mexicanas.

Inician los festejos con la programación del curso México Negro: panorama de la novela criminal contemporánea en México, impartido por el también escritor Eduardo Antonio Parra, quien realizará un repaso sobre las características del género negro, desde su aparición en la literatura anglosajona, su devenir a través de los años, los modelos extranjeros que han influido en los escritores mexicanos para adaptarlos a nuestra cultura y a nuestro país, y subrayará su evolución en la literatura mexicana.

A partir de la segunda sesión hasta el final del curso se comentarán las obras que fueron conformando la novela criminal en México: partiremos Ensayo de un crimen, de Rodolfo Usigli. El complot mongol, de Rafael Bernal, que será la pieza angular del curso, para seguir con Dos crímenes, de Jorge Ibargüengoitia, Cosa fácil, de Paco Ignacio Taibo II, Luna de escarlata, de Rolo Díez, Linda 67, de Fernando del Paso, El miedo a los animales, de Enrique Serna y Balas de plata, de Élmer Mendoza.
Mediante la charla con los participantes se identificará el valor literario de estas obras, y el tipo de sociedad y de país que cada uno de los autores plasmó en sus páginas como telón de fondo de sus historias.

México Negro: panorama de la novela criminal contemporánea en México inicia el próximo martes, 23 de junio, en un horario de 12 a 14 horas.

La segunda invitación responde a una muestra del género negro llevada a la pantalla grande, como parte de los ciclos de Cineclub, que se realizan todos los lunes a las 18:30 horas en el Centro Cultural. El ciclo es Cine negro, y tomará, nuevamente como pretexto para hablar de Bernal, su novela El complot mongol, adaptada al cine en 1977 por Antonio Eceiza. A pesar de no ser una producción de gran factura, la proyección servirá para charlar del escritor, de la obra original y de lo que se queda y lo que se va al realizar esta adaptación.

En ese marco, se contemplan algunas películas que conformarán el ciclo Cine negro. Entre los nombres que están por confirmar se encuentran El Halcón Maltés de John Huston, de 1941, La sombra de una duda, de Alfred Hitchcock, 1943,  Ensayo de un crimen, de Luis Buñuel, 1955, Cadena perpetua, de Arturo Ripstein, 1979 y Terciopelo Azul, de David Lynch, 1986.

Todas las películas, como cada  lunes de Cineclub serán presentadas y comentadas por gente de cine o literatura, especialistas en el tema. La cita es a las 18:30 horas, los lunes del mes de agosto en el Centro Cultural Elena Garro. La entrada es libre.

Sobre los autores

Rafael Bernal nació en la Ciudad de México el 28 de junio de 1915. Sus primeras obras publicadas datan de 1941, pero fue hasta 1969 cuando alcanza un mayor reconocimiento en las letras mexicanas con la publicación de El complot mongol,

Pero la creación literaria de Rafael Bernal fue más que un solo libro. Hizo dramaturgia, cuentos, y programas para radio y televisión. Algunas de sus obras en la línea policiaca son las novelas Su nombre era muerte, Tres novelas policíacas, Un muerto en su tumba. Publicó algunas obras de teatro como Antonia, El maíz en la casa y La paz contigo, de corte histórico y social, y su único libro de versos Improperio a Nueva York y otros poemas.

Bernal fue además un viajero incansable, gracias a su participación en la diplomacia mexicana. Estudió en el Colegio Francés de San Borja y en el Instituto de Ciencias y Letras de Ciudad de México; el bachillerato lo hizo en el Loyola College de Montreal, Canadá. Después de recibir el doctorado en literatura en la Universidad de Friburgo, Suiza,  en 1972, murió a la edad de 57 años.

Eduardo Antonio Parra es narrador y ensayista, autor de cuentos y novelas enmarcadas en la corriente narrativa denominada Literatura del Norte. Entre su obra publicada se encuentran los libros de cuentos Los límites de la noche, Tierra de nadie, Parábolas del silencio; las novelas Nostalgia de la sombra y Juárez. El rostro de piedra. Ha sido merecedor de diferentes premios como el Internacional de Cuento Juan Rulfo 2000, El Premio Nacional de cuento Efrén Hernández 2004 y Premio Antonin Artaud 2010, entre otros galardones.

El Centro Cultural Elena Garro está ubicado en el número 43 de la calle Fernández Leal, en el Barrio de la Concepción, Coyoacán, México, D. F.

Opioides i.v. / I.V. opioids

 Revisión clínica de opioides intravenosos en cuidado agudo
Clinical review of intravenous opioids in acute care
Mark J. McKeen and Sadeq A. Quraishi
Journal of Anesthesiology and Clinical Science 2013,
Abstract
Opioids are routinely used in the management of moderate to severe pain. However, in the acute care setting, consistently undertreated and suboptimally managed pain continues to be a problem. Given the potential for opioids to result in lifethreatening situations, and the increasing complexity of the patients that are cared for in acute care facilities, a thorough understanding of intravenous opioid therapy is a necessity for hospital-based clinicians. Opioids can be classified by chemical structure and/or drug effect (i.e. action on Mu, Kappa, and Delta opioid receptors throughout the body). Endogenous opioids include endorphins, enkephalins, and dynorphins, which moderate the body's natural response to pain. Commonly used exogenous intravenous opioids include morphine, hydromorphone, fentanyl, meperidine, methadone, buprenorphine, butorphanol, and nalbuphine, which vary greatly in potency, duration of action, metabolism, and in their adverse effect profile. A growing body of evidence suggests that patient controlled analgesia may be superior to conventional methods (need for analgesia determined by clinicians) of treating pain in the acute care setting. Newer pump delivery systems may also decrease the risks of human and equipment errors as well as enhance patient safety and satisfaction. The purpose of this review is to help guide clinicians in the safe and effective management of pain in patients requiring intravenous opioid therapy in the acute care setting. Keywords: Acute pain, acute care, opioid, PCA
PDF
Impacto de la edad, sexo y ruta de administración sobre los eventos adversos de los opioides en el departamento de emergencias. Estudio retrospectivo
Impact of age, sex and route of administration on adverse events after opioid treatment in the emergency department: a retrospective study.
Daoust R, Paquet J, Lavigne G, Piette É, Chauny JM.
Pain Res Manag. 2015 Jan-Feb;20(1):23-8.
PDF
Estudio clínico aleatorizado de un protocolo con hidromorfona intravenosa versus el cuidado habitual en el dolor agudo de los ancianos en el departamento de urgencias.
Randomized clinical trial of an intravenous hydromorphone titration protocol versus usual care for management of acute pain in older emergency department patients.
Chang AK, Bijur PE, Davitt M, Gallagher EJ.
Drugs Aging. 2013 Sep;30(9):747-54. doi: 10.1007/s40266-013-0103-y.
Abstract
BACKGROUND AND OBJECTIVES: Opioid titration is an effective strategy for treating pain; however, titration is generally impractical in the busy emergency department (ED) setting. Our objective was to test a rapid, two-step, hydromorphone titration protocol against usual care in older patients presenting to the ED with acute severe pain. METHODS: This was a prospective, randomized clinical trial of patients 65 years of age and older presenting to an adult, urban, academic ED withacute severe pain. The study was registered at http://www.clinicaltrials.gov (NCT01429285). Patients randomized to the hydromorphone titration protocol initially received 0.5 mg intravenous hydromorphone. Patients randomized to usual care received any dose of any intravenous opioid. At 15 min, patients in both groups were asked, 'Do you want more pain medication?' Patients in the hydromorphone titration group who answered 'yes' received a second dose of 0.5 mg intravenous hydromorphone. Patients in the usual care group who answered 'yes' had their ED attending physician notified, who then could administer any (or no) additional medication. The primary efficacy outcome was satisfactory analgesia defined a priori as the patient declining additional analgesia at least once when asked at 15 or 60 min after administration of the initial opioid. Dose was calculated in morphine equivalent units (MEU: 1 mg hydromorphone = 7 mg morphine). The need for naloxone to reverse adverse opioid effects was the primary safety outcome. RESULTS: 83.0 % of 153 patients in the hydromorphone titration group achieved satisfactory analgesia compared with 82.5 % of 166 patients in the usual care group (p = 0.91). Patients in the hydromorphone titration group received lower mean initial doses of opioids at baseline than patients in the usual care group (3.5 MEU vs. 4.7 MEU, respectively; p ≤ 0.001) and lower total opioids through 60 min (5.3 MEU vs. 6.0 MEU; p = 0.03). No patient needed naloxone. CONCLUSIONS: Low-dose titration of intravenous hydromorphone in increments of 0.5 mg provides comparable analgesia to usual care with lessopioid over 60 min.
PDF
Comparación de nalbufina con morfina en sus efectos analgésicos y seguridad. Meta-análisis de estudios aleatorizados controlados
A comparision of nalbuphine with morphine for analgesic effects and safety : meta-analysis of randomized controlled trials.
Zeng Z, Lu J, Shu C, Chen Y, Guo T, Wu QP, Yao SL, Yin P.
Sci Rep. 2015 Jun 3;5:10927. doi: 10.1038/srep10927.
PDF
Atentamente
Anestesia y Medicina del Dolor

domingo, 21 de junio de 2015

Las personas que comen chocolate tienen el corazón más sano


Fuente
Este artículo es originalmente publicado en:
http://www.madrimasd.org/informacionidi/noticias/noticia.asp?id=63923&origen=notiweb&dia_suplemento=martes

Un estudio observa una relación entre el mayor consumo de chocolate y un menor riesgo de sufrir enfermedades cardiovasculares.

FUENTE | El País Digital

Los espacios verdes influyen en el desarrollo cognitivo de los niños


Fuente
Este artículo es originalmente publicado en:
http://www.madrimasd.org/informacionidi/noticias/noticia.asp?id=63921&origen=notiweb&dia_suplemento=martes

Los espacios verdes influyen en el desarrollo cognitivo de los niños, según concluye un estudio con 2.600 alumnos de primaria desarrollado por un equipo científico con participación del Consejo Superior de Investigaciones Científicas(CSIC).

FUENTE | CSIC



Más de bloqueo del plexo braquial/More on brachial plexus block

Comparación de técnicas de bloqueo del plexo braquial axilar guiadas por ultrasonido: inyección perineural contra la infiltración perivascular simple o doble.
Comparison of ultrasound-guided axillary brachial plexus block techniques: perineural injection versus single or double perivascular infiltration.
Cho S, Kim YJ, Baik HJ, Kim JH, Woo JH.
Yonsei Med J. 2015 May;56(3):838-44. doi: 10.3349/ymj.2015.56.3.838.
Abstract
PURPOSE: We compared three methods of ultrasound-guided axillary brachial plexus block, which were single, and double perivascular (PV) infiltration techniques, and a perineural (PN) injection technique. MATERIALS AND METHODS: 78 patients of American Society of Anesthesiologists physical status I-II undergoing surgery of the forearm, wrist, or hand were randomly allocated to three groups. 2% lidocaine with epinephrine 5 μg/mL was used. The PN group (n=26) received injections at the median, ulnar, and radial nerve with 8 mL for each nerve. The PV1 group (n=26) received a single injection of 24 mL at 12-o'clock position of the axillary artery. The PV2 group (n=26) received two injections of 12 mL each at 12-o'clock and 6-o'clock position. For all groups, musculocutaneous nerve was blocked separately. RESULTS: The PN group (391.2±171.6 sec) had the longest anesthetic procedure duration than PV1 (192.8±59.0 sec) and PV2 (211.4±58.6 sec). There were no differences in onset time. The average induction time was longer in PN group (673.4±149.6 sec) than PV1 (557.6±194.9 sec) and PV2 (561.5±129.8 sec). There were no differences in the success rate (89.7% vs. 86.2% vs. 89.7%).
CONCLUSION: The PV injection technique consisting of a single injection in 12-o'clock position above the axillary artery in addition to a musculocutaneous nerve block is equally effective and less time consuming than the PN technique. Therefore, the PV technique is an alternative method that may be used in busy clinics or for difficult cases.
KEYWORDS: Brachial plexus; nerve block; ultrasonography
PDF
Dexmedetomidina como adyuvante de ropivacaína en el bloqueo supraclavicular del plexo braquial
Dexmedetomidine as an adjuvant to ropivacaine in supraclavicular brachial plexus block.
Kathuria S, Gupta S, Dhawan I.
Saudi J Anaesth. 2015 Apr-Jun;9(2):148-54. doi: 10.4103/1658-354X.152841.
Abstract
CONTEXT: Dexmedetomidine as an adjuvant to local anesthetics in peripheral nerve blocks has been used in only a few studies. AIMS: We aimed at assessing the effect of dexmedetomidine as an adjuvant to ropivacaine in supraclavicular brachial plexus block. SETTINGS AND DESIGN:
Random, controlled, and triple blind. MATERIALS AND METHODS: Sixty American Society of Anesthesiologist grade I and II patients of either sex scheduled for elective upper limb surgery under supraclavicular brachial plexus block were divided into three equal groups in a prospective randomized double-blind controlled manner. For block patients in Group C received 0.5% ropivacaine (30cc), 0.5% ropivacaine with 50 μg dexmedetomidine (30cc) in Group D and 0.5% ropivacaine (30cc) in Group D-IV along with intravenous infusion of 50 μg dexmedetomidine in normal saline. STATISTICAL ANALYSIS USED: IBM-SPSS software version 17, Chi-square test, Mann-Whitney U-test. RESULTS: Demographic profile and surgical characteristics were similar in all the three groups. Sensory block and motor block onset was earlier in group D than in group D-IV and group C. The sensory block and motor block duration was also prolonged in group D when compared with group D-IV and group C. The duration of analgesia was significantly longer in group D and D-IV when compared to group C. CONCLUSIONS:
Dexmedetomidine as an adjuvant to 0.5%ropivacaine in ultrasound guided brachial plexus block shortens the sensory as well as motor block onset time, prolongs sensory and motor block duration and also increases the duration of analgesia. The action of dexmedetomidine most probably is local rather than centrally mediated.
KEYWORDS: Dexmedetomidine; ropivacaine; supraclavicular brachial plexus block
PDF
Atentamente
Anestesia y Medicina del Dolor

Hace 2000 días/Two thousand days ago

Hace 2000 dias.
Hace 2000 días, el primero de Enero 2010, iniciamos este Programa Educativo Alfa como un proyecto dedicado a enviar cada día artículos en PDF o en HTML a un reducido grupo de colegas anestesiólogos, intensivistas, cirujanos, internistas, algólogos y especialidades relacionadas, incluyendo enfermeras y estudiantes de medicina. El proyecto inicial se ha convertido en un programa educativo exitoso que llega a 4500 miembros en los cinco continentes, muy en especial a los países de Latinoamérica. Se han enviado 7,540 artículos, 45 libros, varias revistas completas, y videoclips. Además se han promovido cursos, eventos, congresos y enlaces de interés académico. Al principio teníamos dudas sobre su utilidad, pero al paso de los primeros meses vimos con agrado la buena aceptación y crecimiento lento y paulatino del número de subscritores, con un bajo porcentaje de cancelaciones. Hoy en día no solo se envían artículos completos, sino que hemos agregado enlaces a revistas, a libros, videos y recién creamos el correo con la Imagen del Mes, donde se incluyen fotografías clínicas originales adicionadas de información médica disponible en la WEB.
Al paso de estos 2000 días hemos aprendido a seleccionar la información enviada, a escuchar las sugerencias recibidas, a responder las consultas de colegas y pacientes con prontitud, al igual que hemos ido presentando y publicando nuestra propia experiencia en diversos foros y revistas biomédicas. La meta fundamental de nuestro portal www.anestesia-dolor.org es facilitar la educación médica continuada utilizando la información gratuita y selecta disponible en la WEB.
Agradecemos el dejarnos llegar con este programa hasta su ordenador, y se le invita a seguir con nosotros, y a difundir este programa educativo entre sus colegas. Si desea hacer un donativo económico que nos ayude a mejorar este programa le estaremos muy agradecidos.
Aprovechamos la coincidencia de fechas para FELICITAR a todos los colegas que además de llevar en hombros su responsabilidad profesional, hoy celebran el DIA de los PADRES! 

 
2000 days ago, January first 2010, we initiated this Educational Alfa Program as a project dedicated to daily post articles in PDF or HTML to a small group of colleagues anesthesiologists, intensivists, surgeons, internists, pain medicine, and related specialties, including nurses and medical students. The initial project has become a successful educational program that reaches 4,500 members on five continents, most in Latin America countries. We have sent 7,540 articles, 45 books, several full magazines, and video clips. We have also promoted courses, events, conferences and links with academic interest. We initially had doubts about its usefulness, but over the first few months we saw with pleasure the good acceptance and slow and gradual growth in the number of subscribers, with a very low percentage of cancellations. Besides all this, we've added links to journals, books, videos and newly created the Image of the Month, where original clinical photographs and medical information are included.
In these 2000 days we have learned to select the information to be sent, listen to suggestions received, and answer queries from colleagues and patients promptly. We also have been presenting and publishing our own experience in various forums and biomedical journals. The primary goal of our website www.anestesia-dolor.org is to facilitate continuing medical education using select information available free on the Web.
We appreciate letting us get this program to your computer, invite you to follow us, and ask you to spread this education program among your colleagues. If you want to make a financial donation to help us to improve this program we would be very grateful.
We take this coincidence of dates to congratulate all colleagues that in addition to carrying on their shoulders their professional responsibility, today celebrate Father's Day! 
Academic Medicine, Vol. 90, No. 6 / June 2015
American Journal of the Medical Sciences:
April 2015 - Volume 349 - Issue 4
Journal of Clinical Anesthesia
2015  Volume 27, Issue 1, p1-96
Saudi J Anaesth 2015
July-September. Volume 9, Issue 3
Anesthesia & Analgesia 
June 2014 - Volume 118 - Issue 6
Annals of Surgery 
May 2015 - Volume 261 - Issue 5
Journal of Anesthesia & Critical Care: Open Access
2015:3(2)
AACN Advanced Critical Care
April/June 2011 - Volume 22 - Issue 2
British Journal of Pain May 2015
Issue on Cancer Pain
Topics in Public Health
Edited by David Claborn, ISBN 978-953-51-2132-9, 306 pages, Publisher: InTech
Autoimmunity - Pathogenesis, Clinical Aspects and Therapy of Specific Autoimmune Diseases
Edited by Katerina Chatzidionysiou, ISBN 978-953-51-2134-3, 208 pages, Publisher: InTech
Atentamente
Anestesia y Medicina del Dolor